Literature DB >> 27847389

Acute kidney injury from SGLT2 inhibitors: potential mechanisms.

Kai Hahn1, A Ahsan Ejaz2, Mehmet Kanbay3, Miguel A Lanaspa4, Richard J Johnson4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27847389     DOI： 10.1038/nrneph.2016.159

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  5 in total

Review 1.  Fructose and uric acid in diabetic nephropathy.

Authors:  Petter Bjornstad; Miguel A Lanaspa; Takuji Ishimoto; Tomoki Kosugi; Shinji Kume; Diana Jalal; David M Maahs; Janet K Snell-Bergeon; Richard J Johnson; Takahiko Nakagawa
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

2.  Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.

Authors:  Marko Skrtić; Gary K Yang; Bruce A Perkins; Nima Soleymanlou; Yuliya Lytvyn; Maximilian von Eynatten; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Thomas Hach; Melvin Silverman; David Z I Cherney
Journal:  Diabetologia       Date:  2014-10-04       Impact factor: 10.122

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

4.  Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat.

Authors:  H Kitamura; A Yamauchi; T Sugiura; Y Matsuoka; M Horio; M Tohyama; S Shimada; E Imai; M Hori
Journal:  Kidney Int       Date:  1998-01       Impact factor: 10.612

5.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245
  5 in total
  26 in total

Review 1.  Advances in predictive in vitro models of drug-induced nephrotoxicity.

Authors:  Joanne Y-C Soo; Jitske Jansen; Rosalinde Masereeuw; Melissa H Little
Journal:  Nat Rev Nephrol       Date:  2018-06       Impact factor: 28.314

2.  Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report.

Authors:  Christos Pleros; Elisavet Stamataki; Antonia Papadaki; Nikolaos Damianakis; Rafaela Poulidaki; Charikleia Gakiopoulou; Ioannis Tzanakis
Journal:  CEN Case Rep       Date:  2017-11-10

3.  Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy.

Authors:  Liad Hinden; Shiran Udi; Adi Drori; Asaad Gammal; Alina Nemirovski; Rivka Hadar; Saja Baraghithy; Anna Permyakova; Matan Geron; Merav Cohen; Sabina Tsytkin-Kirschenzweig; Yael Riahi; Gil Leibowitz; Yaakov Nahmias; Avi Priel; Joseph Tam
Journal:  J Am Soc Nephrol       Date:  2017-10-13       Impact factor: 10.121

Review 4.  Medication Safety Principles and Practice in CKD.

Authors:  Chanel F Whittaker; Margaret A Miklich; Roshni S Patel; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-18       Impact factor: 8.237

5.  What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.

Authors:  Jessica A Dominguez Rieg; Timo Rieg
Journal:  Diabetes Obes Metab       Date:  2019-04       Impact factor: 6.577

Review 6.  Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?

Authors:  Sidar Copur; Abdullah Yildiz; Carlo Basile; Katherine R Tuttle; Mehmet Kanbay
Journal:  J Nephrol       Date:  2022-08-13       Impact factor: 4.393

7.  SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.

Authors:  Min Zhuo; Julie M Paik; Deborah J Wexler; Joseph V Bonventre; Seoyoung C Kim; Elisabetta Patorno
Journal:  Am J Kidney Dis       Date:  2021-11-08       Impact factor: 11.072

8.  Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.

Authors:  Junki Morino; Keiji Hirai; Shohei Kaneko; Saori Minato; Katsunori Yanai; Yuko Mutsuyoshi; Hiroki Ishii; Momoko Matsuyama; Taisuke Kitano; Mitsutoshi Shindo; Akinori Aomatsu; Haruhisa Miyazawa; Kiyonori Ito; Yuichiro Ueda; Taro Hoshino; Susumu Ookawara; Kazuo Hara; Yoshiyuki Morishita
Journal:  CEN Case Rep       Date:  2019-01-20

9.  Forever Starts Now: Effects of Glucose-Lowering Therapies on Acute Kidney Injury.

Authors:  Sradha Kotwal; Vlado Perkovic
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-29       Impact factor: 8.237

Review 10.  COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course.

Authors:  Cyril P Landstra; Eelco J P de Koning
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-17       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.